# Stepan

Type: Company (SCL)

Source: GetYourBrief — https://getyourbrief.com/entity/stepan
Canonical HTML page: https://getyourbrief.com/entity/stepan

## Timeline

- **2025-12-31**: Patent Extension — Secured Rezdiffra patent protection through 2045.
- **2025-11-20**: DGAT-2 and siRNA Expansion — Acquired late-stage DGAT-2 inhibitor and six preclinical siRNA assets.
- **2025-09-15**: GLP-1 Acquisition — Madrigal paid $120 million upfront to acquire an oral GLP-1 program.
- **2025-03-01**: Rezdiffra Commercial Launch — First full year of Rezdiffra availability in the U.S. market for MASH.

## Recent coverage (2 stories, network-wide)

### Madrigal’s Rezdiffra Surpasses $950M in 2025 as Pipeline Expands into GLP-1s
2026-02-24 00:14:25 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 5

Madrigal Pharmaceuticals reported a transformative 2025, with Rezdiffra net sales reaching $958.4 million during its first full year on the market. The company is aggressively pivoting toward a multi-asset metabolic powerhouse, integrating oral GLP-1 and DGAT-2 programs alongside its core MASH franchise.
Full story: https://getbiobrief.com/story/madrigal-pharma-q4-2025-earnings-rezdiffra-growth

### Q4 Earnings: Carvana and Freshpet Lead Digital-First Retail Surge
2026-02-24 00:10:34 · Sector: retail · Sentiment: Positive · Impact: 7/10 · Sources: 5

The Q4 2025 earnings cycle reveals a retail landscape defined by digital efficiency and premiumization, with Carvana and Freshpet posting double-digit volume growth. Companies are increasingly leveraging loyalty ecosystems and strategic partnerships to drive margins in a stabilizing consumer market.
Full story: https://getretailbrief.com/story/q4-2025-ecommerce-retail-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.